Provided herein are methods for maintaining physiological levels of nitrite in a subject undergoing hemodialysis. Also provided herein are methods of administering pharmaceutically acceptable sodium nitrite to a subject undergoing hemodialysis.

The invention relates to supramolecular metal coordinated liothyronine (triiodothyronine, T3) compositions, methods of preparing such compositions, methods of purifying and formulating supramolecular metal coordinated liothyronine, and methods of treating hypothyroidism and other disease states using such compositions.

The invention relates to supramolecular metal coordinated liothyronine (triiodothyronine, T3) compositions, methods of preparing such compositions, methods of purifying and formulating supramolecular metal coordinated liothyronine, and methods of treating hypothyroidism and other disease states using such compositions.

A composition comprising a hydrogen peroxide source and at least one metal halide. The hydrogen peroxide source comprises hydrogen peroxide and a means for generating hydrogen peroxide. The means for producing hydrogen peroxide comprises at least one oxidoreductase and at least one oxidoreductase substrate. The oxidoreductase substrate comprises at least one sugar, said sugar located within the composition. The composition is held under conditions that render the components inactive until rehydrated.

A composition comprising a hydrogen peroxide source and at least one metal halide. The hydrogen peroxide source comprises hydrogen peroxide and a means for generating hydrogen peroxide. The means for producing hydrogen peroxide comprises at least one oxidoreductase and at least one oxidoreductase substrate. The oxidoreductase substrate comprises at least one sugar, said sugar located within the composition. The composition is held under conditions that render the components inactive until rehydrated.

The invention provides antimicrobial compositions comprising charged cellulose nanofibrils dispersed in an aqueous solution having a dissolved oxygen content of at least 20 mg/L, preferably from 20 to 100 mg/L. The cellulose nanofibrils may have an increased surface charge due to their carboxylic acid content which contributes to their antimicrobial properties. In particular, the carboxylic acid content may be at least about 1000 μmol/g cellulose, preferably at least about 1400 μmol/g cellulose. The compositions are suitable for use in the treatment of wounds, in particular chronic wounds.

The invention provides antimicrobial compositions comprising charged cellulose nanofibrils dispersed in an aqueous solution having a dissolved oxygen content of at least 20 mg/L, preferably from 20 to 100 mg/L. The cellulose nanofibrils may have an increased surface charge due to their carboxylic acid content which contributes to their antimicrobial properties. In particular, the carboxylic acid content may be at least about 1000 μmol/g cellulose, preferably at least about 1400 μmol/g cellulose. The compositions are suitable for use in the treatment of wounds, in particular chronic wounds.

The invention pertains to the use of soluble sodium in the manufacture of a composition or kit of parts for (therapeutically) improving and prolonging blood plasma uridine levels and tissue availability of uridine, and/or for treating or preventing impaired blood plasma uridine levels and tissue availability of uridine, and/or for preventing/treating disorders associated with impaired blood plasma and tissue availability of uridine, in a mammal, preferably a human being, by orally co-administering soluble sodium and uridine in a molar ratio of soluble sodium to uridine of more than 1:1, preferably more than 1.5:1, more preferably more than 2:1, even more preferably at least 2.5:1, even more preferably at least 2.8:1, more preferably 3:1-15:1, most preferably 3:1-10:1, particularly 3:1-5:1.

The invention pertains to the use of soluble sodium in the manufacture of a composition or kit of parts for (therapeutically) improving and prolonging blood plasma uridine levels and tissue availability of uridine, and/or for treating or preventing impaired blood plasma uridine levels and tissue availability of uridine, and/or for preventing/treating disorders associated with impaired blood plasma and tissue availability of uridine, in a mammal, preferably a human being, by orally co-administering soluble sodium and uridine in a molar ratio of soluble sodium to uridine of more than 1:1, preferably more than 1.5:1, more preferably more than 2:1, even more preferably at least 2.5:1, even more preferably at least 2.8:1, more preferably 3:1-15:1, most preferably 3:1-10:1, particularly 3:1-5:1.

The present invention provides a nitric-oxide containing composite in the form of microparticles, wherein said microparticles comprise: (i) a core which comprises silica; (ii) a layer on said core which comprises a metal-organic framework; and (iii) nitric oxide;
wherein said metal-organic framework comprises organic ligands comprising at least one amine group, said metal-organic framework is uniformly distributed on the surface of said silica core and said nitric oxide is chemisorbed within said metal-organic framework.